Generative AI-Designed Drug Enters Phase II Clinical Trials for Chronic Lung Disease
Insilico Medicine has advanced the first generative AI-discovered and AI-designed drug candidate into Phase II clinical trials. The drug, INS018_055, targets idiopathic pulmonary fibrosis, a chronic condition that causes progressive…